Maxim cuts Acrivon PT on deprioritization of ovarian and bladder programs
Maxim Group cuts PT on drug developer Acrivon Therapeutics ACRV.O to $7 from $24
Cites deprioritization of ovarian and bladder programs
"Management announced that due to a higher bar in ovarian cancer and difficulty recruiting OncoSignature positive patients in bladder cancer, the company is deprioritizing these programs," says brokerage
Adds the data in endometrial cancer is still quite strong and with a positive safety profile
New PT is ~245% upside to stock's last close
Nine of 10 brokerages rate stock "buy" or higher, and 1 "hold"; median PT is $15 - data compiled by LSEG
ACRV shares down ~66% YTD, as of last close; they rose ~22% in 2024
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Tradingkey







